[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Trauma Hemostatis and Oxygenation Research (THOR) Network\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100613381","phase-4-fibrinogen-in-liver-transplant-100613381",false,"NCT07265843","Fibrinogen in Liver Transplant","Fibrinogen in Liver Transplant Subjects (FITS)","Inclusion Criteria:\n\n* 18 years of age or older\n* Scheduled to undergo cadaveric liver transplant\n* Meets at least one of the following criteria:\n* Baseline fibrinogen \\\u003C200 mg\u002FdL or clinically significant visoelastic testing,\n* Alcoholic cirrhosis,\n* Nonalcoholic Steatohepatitis (NASH),\n* HCV infection\n\nExclusion Criteria:\n\n* Living related donor transplant,\n* Known prothrombotic disorder,\n* Patient objection to blood transfusion,\n* Known severe allergic reaction to plasma-based products,\n* IgA deficiency with known hypersensitivity reaction to plasma,\n* Hepatocellular\u002Fcholangio carcinoma,\n* Primary biliary fibrosis","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The study is a prospective, multi-centered, unblinded, randomized controlled pilot study. The primary objective is to compare functional hemostatic capacity of two approved products Intercept Fibrinogen Complex (IFC) to Standard Cryoprecipitate Antihemophilic Factor (AHF) for liver transplant patients with bleeding and hypofibrinogenemia to determine impact of earlier access to a concentrated source of fibrinogen in a goal-directed manner.",[26],"Liver Transplant Surgery",[28],"Cryoprecipitate","NOT_YET_RECRUITING","2025-12-01",{"date":32,"type":33},"2025-12-05","ACTUAL",{"date":35,"type":20},"2026-01-01",{"date":37,"type":20},"2028-03-01",{"name":39,"class":40},"Trauma Hemostatis and Oxygenation Research (THOR) Network","OTHER",""]